Product Information
FIRVANQ 50 MG/ML SOLUTION is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $1.1860 per ML under NDC 65628020605. Its NADAC has been published 394 times since Aug 22, 2018.
FDA first approved this application on Jan 26, 2018. Its Orange Book therapeutic-equivalence code is AA.
Manufacturer
Azurity Pharmaceuticals Inc.NDC
65628020605
Classification
Brand
Dosage Form
KIT
Effective Date
1/1/2026
Approval Type
New Drug (NDA)
FDA Application
NDA208910FDA Approved
1/26/2018
TE Code
AA
On Market Since
1/26/2018
Price Statistics
The NADAC for FIRVANQ 50 MG/ML SOLUTION has been published 394 times since Aug 22, 2018, and over the history we have for it it has risen 47.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.1860 per ML |
|---|---|
| All-time high | $1.1860 (Sep 30, 2026) |
| All-time low | $0.8030 (Aug 22, 2018) |
| 52-week high | $1.1860 |
| 52-week low | $1.1515 |
| Median price | $0.9201 |
| Average price | $0.9626 |
| Largest weekly change | +11.3% (Jun 19, 2024) |
| Weeks tracked | 394 |
| Tracking since | Aug 22, 2018 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 67% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Azurity Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
vancomycin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FIRVANQ 50 MG/ML SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for FIRVANQ 50 MG/ML SOLUTION, manufactured by Azurity Pharmaceuticals Inc., is $1.1860 per ML (NDC 65628020605), effective Sep 30, 2026.
How has the price of FIRVANQ 50 MG/ML SOLUTION changed over time?
Over the history we have for it, the NADAC for FIRVANQ 50 MG/ML SOLUTION has risen 47.7%. It has been tracked across 394 weekly CMS publications since Aug 22, 2018.
What are the highest and lowest recorded NADAC prices for FIRVANQ 50 MG/ML SOLUTION?
Since Aug 22, 2018, the NADAC for FIRVANQ 50 MG/ML SOLUTION has ranged from a low of $0.8030 (Aug 22, 2018) to a high of $1.1860 (Sep 30, 2026), with a median of $0.9201 per ML.
Are there cheaper alternatives to FIRVANQ 50 MG/ML SOLUTION?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VANCOMYCIN 25 MG/ML ORAL SOLN, is $0.3900 per ML — about 67% below FIRVANQ 50 MG/ML SOLUTION.
Who manufactures FIRVANQ 50 MG/ML SOLUTION?
FIRVANQ 50 MG/ML SOLUTION (NDC 65628020605) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.